Followers | 16 |
Posts | 1145 |
Boards Moderated | 0 |
Alias Born | 03/12/2010 |
Saturday, January 07, 2017 4:10:49 AM
ProMIS Neurosciences initiates groundbreaking Cohort Study
Results could pave the way for precision medicine treatment of Alzheimer’s
TORONTO, Nov. 8, 2016 /CNW/ – ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced initiation of a Cohort Study to evaluate the prevalence of different strains of Amyloid beta (Ab) prions in patients with Alzheimer’s disease (AD). The first results of the Cohort Study are anticipated in Q1 2017.
“The Cohort Study will use ProMIS’s five recently validated monoclonal antibodies (mAbs) to detect specific prion targets (epitopes) in samples from AD patients,” stated ProMIS CSO Dr. Neil Cashman. “To our knowledge, this is the first program aimed at generating a broad dataset to assess the prevalence of different A? prion strains in AD patients”.
The Cohort Study is being conducted in the laboratories of ProMIS CSO, Dr. Neil Cashman. The study will use cerebrospinal fluid (CSF) samples from more than 100 patients with dementia, collected over an eight-year period by Dr. Robin Hsiung, Associate Professor of Neurology at the University of British Columbia. The detailed clinical and laboratory data accompanying some of the samples may also lead to the identification of prion strains associated with more rapid disease progression and/or more prevalent in certain patient subgroups.
“This revolutionary Cohort Study may provide important evidence supporting a critical role for our antibodies in AD,” stated ProMIS Executive Chairman, Eugene Williams. “First, detection of prion targets in CSF samples using our specific mAbs may not only allow to confirm diagnosis of AD but also to determine what subgroup of AD is present, based on which Ab prion targets are detected. Second, these mAbs, after humanization and scale-up, could offer the greatest chance for effective treatment specifically targeted to these subgroups of AD patients, and ultimately may lead to their use for prevention of disease.”
As results of the Cohort Study emerge, the Company plans to pursue multiple research collaborations to further support its precision medicine approach to AD. ProMIS is also evaluating the feasibility and development of a blood-based detection method, which would enable broad screening of patients at risk or suspected of having AD.
Commenting on the Company’s program, Mara Aspinall, a recognized expert in precision medicine and member of the ProMIS Business Advisory Board, stated: “Alzheimer’s Disease has all the hallmarks for the next breakthrough in personalized medicine – a complex disease with variable presentation and prognosis. ProMIS insights and anticipated outcomes of the Cohort Study could represent an important, fundamental shift in our approach to precision diagnosis and treatment of AD.”
Recent PMN News
- ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences • GlobeNewswire Inc. • 09/12/2024 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/09/2024 08:10:10 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/09/2024 08:05:20 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/09/2024 04:15:07 AM
- ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2024 11:00:00 AM
- ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology • GlobeNewswire Inc. • 08/06/2024 11:00:00 AM
- ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024 • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference • GlobeNewswire Inc. • 07/30/2024 12:30:00 PM
- ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial • GlobeNewswire Inc. • 07/26/2024 12:35:00 PM
- ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing • GlobeNewswire Inc. • 07/26/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:25:22 PM
- ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights • GlobeNewswire Inc. • 05/14/2024 08:01:00 PM
- ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS • GlobeNewswire Inc. • 04/09/2024 11:00:00 AM
- ProMIS Neurosciences to Present in Upcoming Investor Conferences in April • GlobeNewswire Inc. • 04/04/2024 11:00:00 AM
- ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 04/01/2024 08:15:00 PM
- ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine • GlobeNewswire Inc. • 01/22/2024 12:00:00 PM
- ProMIS Neurosciences Issues Letter to Shareholders • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
- ProMIS Neurosciences, Inc. Announces Leadership Transition • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- ProMIS Neurosciences Announces Publication on Novel Target for ALS • GlobeNewswire Inc. • 12/20/2023 12:00:00 PM
- ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease • GlobeNewswire Inc. • 11/20/2023 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM